Clinical Trial Update: Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating a Genitope gp100 vaccine with rituximab and sargramostim for patients with refractory or progressive Non-Hodgkin lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Genitope gp100 vaccine (gp100 peptide vaccine)
• Rituximab (rituximab)
• sargramostim (sargramostim)

Snippet

Sponsor: Genitope Corporation | Conditions: Lymphoma | Phase 2 | Status: COMPLETED